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The availability of a diagnostic test to detect subclinical leprosy cases is crucial to interrupt
the transmission of M. leprae. In this study we assessed the minimum sensitivity level of
such a (hypothetical) diagnostic test and the optimal testing strategy in order to effectively
reduce the new case detection rate (NCDR) of leprosy.
Methods and findings
We used the individual-based model SIMCOLEP, and based it on previous quantification
using COLEP data, a cohort study of leprosy cases in Bangladesh. The baseline consisted
of treatment with Multidrug therapy of clinically diagnosed leprosy cases, passive case
detection and household contact tracing. We examined the use of a leprosy diagnostic test
for subclinical leprosy in four strategies: testing in 1) household contacts, 2) household con-
tacts with a 3-year follow-up, 3) a population survey with coverage 50%, and 4) a population
survey (100%). For each strategy, we varied the test sensitivity between 50% and 100%. All
analyses were conducted for a high, medium, and low (i.e. 25, 5 and 1 per 100,000) endemic
setting over a period of 50 years.
In all strategies, the use of a diagnostic test further reduces the NCDR of leprosy com-
pared to the no test strategy. A substantial reduction could already be achieved at a test sen-
sitivity as low as 50%. In a high endemic setting, a NCDR of 10 per 100,000 could be
reached within 8–10 years in household contact testing, and 2–6 years in a population test-
ing. Testing in a population survey could also yield the highest number of prevented new
cases, but requires a large number needed to test and treat. In contrast, household contact
testing has a smaller impact on the NCDR but requires a substantially lower number needed
to test and treat.
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Conclusions
A diagnostic test for subclinical leprosy with a sensitivity of at least 50% could substantially
reduce M. leprae transmission. To effectively reduce NCDR in the short run, a population
survey is preferred over household contact tracing. However, this is only favorable in high
endemic settings.
Author summary
The annual number of new leprosy cases has been stable in the past decade, indicating
that transmission has not been yet been interrupted. As current control seems to be insuf-
ficient to bring down the number of cases, there is a need for novel tools to interrupt
transmission. A diagnostic that permitted diagnosis of subclinical cases will likely be fun-
damental to achieve elimination and ultimately eradication. In this study we assessed the
minimum sensitivity level of such a (hypothetical) diagnostic test and the optimal testing
strategy in order to effectively reduce the new case detection rate (NCDR) of leprosy. We
showed that a diagnostic test for subclinical leprosy could substantially reduce the NCDR
in a high, medium and low endemic population. A significant impact could already be
achieved at a test sensitivity level of 50%. To effectively reduce the NCDR in the short run,
a population survey is preferred over household contact tracing. However, this is only
favorable in high endemic settings, as in medium and low endemic settings testing in a
population survey requires many more people to be tested and treated to prevent one new
leprosy case.
Introduction
Leprosy is an infectious disease caused by Mycobacterium leprae, affecting the skin, peripheral
nerves, the mucosa of the upper respiratory tract and the eyes [1]. The most likely route of
transmission of M. leprae is via the aerosolic route [2]. Individuals, who have close and fre-
quent contact to a patient with leprosy, in particular within households, have the highest risk
of acquiring the infection and developing leprosy [3, 4]. Currently, the main strategy to control
leprosy, as recommended by the World Health Organization (WHO), is early detection of
cases and treatment with multidrug therapy (MDT) [5]. Leprosy is diagnosed by clinicians
based on the clinical signs and symptoms, along with the use of slit-skin smears and biopsies
to respectively detect the presence of acid-fast bacteria and determine type of leprosy histologi-
cally [6].
Although the prevalence of leprosy has dropped immensely in the last 30 years, worldwide
still more than 200,000 new cases of leprosy are detected annually [5]. This number has
remained fairly stable over the last decade, indicating that transmission has not yet been inter-
rupted. Global elimination has been a target since 1991, and more recently the target for lep-
rosy has been set to achieve zero transmission [7, 8]. However, it is clear that the current
strategy is not sufficient to achieve the goals within a reasonable time frame [9, 10]. For this
reason, alternative strategies should be considered. Previous modeling studies have shown that
treating people during the subclinical stage of leprosy has a larger impact on the new case
detection rate (NCDR) than early (clinical) diagnosis and treatment [11]. Therefore, inter-
ventions such as the provision of chemoprophylaxis (antibiotics) or immunoprophylaxis
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(vaccination) to contacts of leprosy cases could substantially further reduce the NCDR [12–
14]. Nevertheless, these are not yet routinely available nor accepted. A more efficient approach
would be the use of a diagnostic test that allows identification of M. leprae infected individuals
who are at risk of developing leprosy and constitute the major source of transmission.
The identification and validation of new sensitive biomarkers for M. leprae infection and
(subclinical) leprosy is currently investigated in several leprosy endemic areas [15–19]. Host
immunity after M. leprae infection is determined by host genetics, leading to a complex
immuno-pathological spectrum associated with either dominant cellular or humoral immu-
nity. The immune-mediated pathological leprosy spectrum compels detection of M. leprae
infection to be based on multiple, diverse biomarkers specific for cellular as well as humoral
immunity [15, 19]. The use of serological proteomics can help to unravel the biological path-
way in the immunomodulation of leprosy for diagnostic purposes [20]. In addition, pathogen-
based approaches identifying the presence of M. leprae in skin smears of contacts and patients
may offer additional tools for prophylactic targeting [21, 22]. The availability of a specific and
robust diagnostic test to detect infected individuals lacking clinical symptoms, would not only
be beneficial to identify and treat cases at early stages before irreversible damage occurs but
may also be crucial for breaking the transmission chain. As the prevalence of leprosy decreases,
leprosy health care has been integrated into general health care causing decreased clinical
expertise for diagnosing leprosy, leading to extended delays of diagnosis and as a result mainte-
nance or re-emergence of infection. Implementation in general health care of a user- and
field-friendly diagnostic test specific for leprosy may accommodate for the lack of leprologists
in the field.
In this study we aim to identify the minimum requirements of an as yet hypothetical diag-
nostic test for subclinical leprosy (i.e. identifying infected individuals who will progress to dis-
ease) and its potential impact on the NCDR. In order to predict the added value, non-linearity
of infectious disease patterns in the transmission process needs to be taken into account. For
this purpose, we will use the individual-based model SIMCOLEP, which models M. leprae
transmission and control of leprosy in a population structured by households. The model has
previously been used to estimate future NCDR trends in Bangladesh, India, Brazil, and Indo-
nesia, and to test the impact of various interventions targeting household contacts [9–11, 23,
24]. We use SIMCOLEP to assess the impact of a diagnostic test on NCDR under various
assumptions of sensitivity, ranging from 50 to 100%. Furthermore, we investigate the optimal
strategy of using such a test: household contact testing or a population survey. As the impact of
test strategies might be dependent on the endemicity level, all analysis were conducted in a




We used the individual-based model SIMCOLEP that simulates the spread of M. leprae in a
population structured in households. It models life-histories of individuals, which are born
and placed into households. Over time, individuals can create their own household or move to
another household after marriage, during adolescence or after becoming a widow(er). Deaths
of individuals are determined by death rates at birth [23, 26].
In the model, M. leprae transmission occurs when a susceptible individual has contact with
an infectious individual. In the model, susceptibility of an individual to leprosy is randomly
assigned. We assumed that 20% of the population is susceptible, implying that 80% will not
develop leprosy, although the proportion of susceptibles is likely to be lower [1]. This
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assumption was made because a previous modeling study showed that assuming 20% suscepti-
bles provided the best fit and that results did not significantly differed from assuming 5% or
10% susceptibles [23]. Two transmission processes are modeled separately: transmission in the
general population and within-household transmission. The latter can be regarded as an addi-
tional probability of acquiring the infection if household contacts are infected. Infectivity is
determined by the product of the contact rate, both in the general population and within
households, and the probability of infection during a contact. An infected individual develops
either paucibacillary (PB) or multibacillary (MB) leprosy, which is randomly determined
based on the distribution of the type of leprosy. We assumed that only MB leprosy is infectious.
After infection, an individual enters the asymptomatic state, which on average lasts 4.2 years
for PB and 11.1 years for MB. Afterwards the individual proceeds to the symptomatic state,
which lasts on average 5 years for PB leprosy after which self-healing occurs. An MB leprosy
case remains symptomatic until treatment or death. The natural history of leprosy is modeled
following Meima et al. [27]. The model also replicates control measures including treatment
with multidrug therapy (MDT), passive case detection, and household contact tracing. All
detected cases receive MDT treatment, and will not be infectious from then on. Relapses
occurred with a rate of 0.001 per year. 90% relapses to MB and 10% to PB. A full description of
the model can be found in Fischer et al. 2010 and Blok et al. 2015 [9, 23].
Model quantification
We used previously published quantifications of the model based on the population and lep-
rosy epidemiology in Nilphamari and Rangpur districts in Bangladesh. A full description of
the data used to parameterize the birth, household movements and deaths of individuals, and
leprosy epidemiology can be found in Fischer et al. 2010 [23].
Transmission of M. leprae was previously calibrated using data from the COLEP study [4].
The COLEP study population consisted of contacts of 1037 consecutively found new patients
with leprosy in Nilphamari and Rangpur districts in Bangladesh. The data contain information
about the genetic distance (i.e. kinship) of almost 22,000 contacts and were used to fit the prev-
alence of cases among contacts of different household sizes, the prevalence of cases among dif-
ferent types of relatives in 2003. Quantifications were not updated to more recent numbers,
because a trial with chemoprophylaxis started afterwards. Our main focus was to estimate the
impact of a diagnostic test for detection and subsequent effective treatment of M. leprae
infected individuals progressing to disease, in addition to the mainstay control program, as
recommended by the WHO [25]. The transmission contact rate in the general population and
within household was set to 1.33 and 0.98, respectively [23]. The baseline NCDR of Nilphamari
and Rangpur was 27 per 100,000 and the MB/PB ratio 20/80 in 2003 [4].
The leprosy control program in the modeled area was well-organized [28]. It consisted of
passive case detection with an annual detection delay of on average of 2 years (standard devia-
tion 1.4 years) [29] and continuous household contact tracing with a coverage of 90% [23].
During contact tracing only clinical leprosy cases can be diagnosed. We further included the
protective effect of BCG vaccination prior to the infection, which was set to 60% [13]. In order
to reflect a high, medium and low endemic setting, we ran the model given the current control
until it reached a NCDR level of 25 per 100,000, 5 per 100,000 and 1 per 100,000. This was
obtained after 2, 18 and 40 years, respectively.
Scenarios
In different scenarios, we evaluated the impact of using a diagnostic test for subclinical leprosy
on the NCDR trend under various sensitivity levels, ranging from 50% to 100%. We neglected
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lower levels of sensitivity, because it is not expected that such a diagnostic test will come on the
market. Individuals testing positive will be treated with MDT [30].
We evaluated four testing strategies with a diagnostic test for subclinical leprosy in addition
to the current leprosy control:
1. Testing in household contacts of index patients without follow-up. All household contacts of
an index case were traced, clinically examined and tested with the diagnostic test for sub-
clinical leprosy. Household contact testing was rolled out as a continuing routine program.
2. Testing in household contacts of index patients with a 3-year follow-up. All household con-
tacts of an index patient were traced, clinically examined and tested using the diagnostic
test for subclinical leprosy. All contacts were followed-up for a period of 3 years. During fol-
low-up, all household contacts that were not positive before are clinically examined and
tested again (once every follow-up). This testing strategy was rolled out as a continuing rou-
tine program.
3. Testing in a population survey with a coverage of 50%. Half of the population is clinically
examined and tested during a one-time population survey.
4. Testing in a population survey with a coverage of 100%. The whole population is clinically
examined tested during a one-time population survey.
All scenarios were compared to the no-testing strategy which only consisted of the current
leprosy control program. Leprosy cases under treatment were excluded from testing. Testing
compliance in individuals was assumed to be 100%. All strategies were evaluated in terms of
its impact on the NCDR and its benefit and costs. The benefit of a testing strategy was mea-
sured by the number of prevented new leprosy cases calculated as the difference between the
new cases (detected and undetected) of a testing strategy and the no-testing strategy. The costs
of a testing strategy were measured in terms of number needed to test and treat. As tests that
are not completely predictive may produce false positives, we assessed the number needed to
treat given a test specificity of 100%, 95% and 85%. The impact on NCDR, and the benefits
and costs of all strategies were evaluated in a high, medium and low endemic setting. The
modeled time span was a 50-year period.
In a sensitivity analysis, we varied the passive case detection delay and MB/PB ratio. First,
we increased the passive case detection delay to six years, representing an area with a less well-
organized leprosy control program in place. Second, we increased the MB/PB ratio to 65/35,
representing an area with relatively more MB than PB cases. The latter is relevant because we
assume that only MB leprosy is contagious.
Results
Fig 1 presents the impact of a diagnostic test used in household contacts without follow-up
and with a 3-year follow-up, and a one-time population survey with a coverage of 50% and
100% on the NCDR under various assumptions of test sensitivities. In all strategies, the use of
a diagnostic test further reduces the NCDR of leprosy compared to the no-testing scenario.
Household contact testing without follow-up decreases the NCDR gradually over time with
slightly larger effects at higher levels of test sensitivities. If household contacts are additionally
followed-up for 3 years, the impact of lower test sensitivities increases to the level of the highest
test sensitivity. In a population survey of 50% and 100%, a substantial reduction can be seen in
the short run followed by a gradual decline afterwards. The impact varies with sensitivity levels
of the test: a higher sensitivity level of the test corresponds with a larger impact on the NCDR.
In the short run, both population survey testing strategies result in a larger decrease in the
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NCDR than household contact testing. In a population survey with a coverage of 100%, the
NCDR could be 40% lower within 10 years with a test sensitivity of at least 60% (See S1 Fig). In
the long run, the impact of household contact testing on NCDR may be larger than that of a
population survey, depending on the coverage and test sensitivity. In a high endemic setting, a
NCDR of 10 per 100,000 could be reached within ten and eight years in household contact test-
ing without and with follow-up, respectively. In a population survey testing strategy with a
coverage of 50% and 100% this level could be reached within six and two years, respectively.
The relative impact clearly varies with endemicity level with the high endemic setting showing
the largest relative decrease, followed by medium and low endemic setting.
The number needed to test in order to prevent one new leprosy case decreases with level of
sensitivity and increases with the endemicity level of the setting (see Fig 2). Household contact
testing without and with follow-up require substantially fewer individuals to be tested to
Fig 1. Impact of a diagnostic test used in household contacts and a population survey on the NCDR under various
assumptions of sensitivity in a high, medium and low endemic setting. Four strategies were assessed: testing in 1)
household contacts without follow-up, 2) household contacts with a 3-year follow-up, 3) a population survey with a
coverage of 50%, and 4) a population survey with a coverage of 100%. Test sensitivities vary between 50% and 100%. The
black line represents a strategy in which no diagnostic test was used (i.e. continuation of current control). High endemic is
defined as 25 per 100,000 population, medium as 5 per 100,000, and low as 1 per 100,000.
https://doi.org/10.1371/journal.pntd.0006529.g001
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prevent one leprosy case compared to both population survey strategies. In a one-time popula-
tion survey, testing in a high endemic setting requires the least number of people to be tested
to prevent one new leprosy case. In a medium and low endemic setting this number is up to
four and twenty-three times higher, respectively.
Table 1 summarizes the benefits and costs of all testing strategies with an assumed test sen-
sitivity of 70% in a population of 1 million after 10 years. The numbers of prevented cases are
approximately up to ten times higher in a population survey than in household contact testing.
The highest number of prevented cases could be achieved in a high endemic setting. However,
testing in a population survey would require substantially more people to be tested and treated
than household contact testing. If the test is not completely specific, the number needed to treat
further increases as a result of an increased number of false positives. This increase is much
larger in a population survey than household contact testing, as more people are tested in a pop-
ulation survey. The costs of household contact testing decrease with the level of endemicity,
whereas the costs of a population survey do not differ much across endemic settings.
Fig 2. Number needed to test to prevent one new leprosy case. Results present the efficiency of a diagnostic test in
household contacts and a population survey under various assumptions of sensitivity in a high, medium and low endemic
setting. High endemic is defined as 25 per 100,000 population, medium as 5 per 100,000, and low as 1 per 100,000.
https://doi.org/10.1371/journal.pntd.0006529.g002
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S1 Table provides the results of our sensitivity analysis. The number of prevented new lep-
rosy cases is smaller in a setting with a less well-organized leprosy control program compared
to a well-organized setting (i.e. Nilphamari and Rangpur districts in Bangladesh). In a setting
with a high MB/PB ratio, more new leprosy cases can be prevented in a 10-year period. The
number needed to test and treat is to a large extent comparable across all leprosy settings.
Discussion
This paper assessed the impact of the use of a (hypothetical) diagnostic test for subclinical lep-
rosy cases with a sensitivity that ranged between 50% and 100% on the NCDR in household
contact testing and one-time population survey strategies. All strategies showed an additional
reduction in the NCDR over time compared to the current control for all levels of sensitivity
in a high, medium and low endemic setting. Testing in a population survey yields a higher
impact on the NCDR in the short run compared to household contact tracing. In terms of pre-
vented cases, a population survey is preferred over household contact testing. However, a pop-
ulation survey requires much more people to be tested and treated, especially in medium and
low endemic setting, compared to household contact testing.
Our findings indicate that a test with a sensitivity as low as 50% could already result in a sig-
nificant reduction of the NCDR. This suggests that to reduce transmission the availability of a
diagnostic test for subclinical cases is more important than the level of sensitivity, which is
very promising. Moreover, the impact of a test with a low test sensitivity could be increased by
repeating the test in individuals testing negative. We showed that a test with a sensitivity of
50% used in a household contact testing strategy with a 3-year follow-up could reach a similar
impact as a test with a sensitivity of 100%.
Testing in a population survey is most favorable to achieve short term reductions of NCDR
in a high, medium and low endemic setting. The lower impact of household contact tracing
compared to a population survey, especially in the short run, is primarily due to the limited
exposure of the test that is confined to a household with an average size between 4 to 5 persons.
A population survey would also result in a higher number of prevented new leprosy cases.
However, it requires testing of many individuals and thereby commitment by the national
Table 1. Number of prevented new leprosy cases and number needed to test and treat in a population of 1 million after 10 years using a test with 70% sensitivity.
Endemicity a Strategy Prevented new leprosy cases Number needed to test Number needed to treat
100% b 95% b 85% b
High Household contact tracing without follow-up 200 10,700 160 690 1,700
Household contact tracing with 3-year follow-up 500 83,400 300 4,400 12,700
Population survey (50%) 990 479,800 390 24,400 72,300
Population survey (100%) 1,910 959,700 780 48,700 144,700
Medium Household contact tracing without follow-up 40 2,200 30 140 360
Household contact tracing with 3-year follow-up 99 16,500 60 870 2,500
Population survey (50%) 220 483,800 100 24,300 72,700
Population survey (100%) 420 967,700 210 48,600 145,300
Low Household contact tracing without follow-up 9 500 6 30 80
Household contact tracing with 3-year follow-up 19 3,500 11 180 530
Population survey (50%) 45 487,200 21 24,400 73,100
Population survey (100%) 86 974,300 42 48,800 146,200
a High is defined as 25 per 100,000 population, medium as 5 per 100,000, and low as 1 per 100,000)
b Assumed test specificity: 100%, 95% and 85%
https://doi.org/10.1371/journal.pntd.0006529.t001
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leprosy control programs. Such an approach is only favorable and feasible in high endemic set-
tings. Our results show that the numbers needed to test to prevent one new leprosy case in a
medium and low endemic setting are approximately fourfold and twenty-threefold that of a
high endemic setting, respectively.
Although tests specificity is of less importance if we aim to reduce transmission of M. leprae,
it is relevant for determining the optimal testing strategy. If a test is not completely specific,
the number needed to treat may increase dramatically. As the number of people tested is
higher in a population survey than in household contact testing, it would also produce many
more false positives (See Table 1). A solution to reduce the number of false positive is to apply
a two-step approach, whereby a second test with high specificity is added [30].
Our study also highlights that the target of zero transmission might be difficult to achieve,
even with a well-organized control program and the use of a diagnostic test for subclinical
cases. Over a 50-year period, our model predicted that the NCDR in the high, medium and
low endemic setting would be at most reduced to very low levels: 0.10–0.50, 0.01–0.10, and
0.005–0.025 per 100,000 in a high, medium and low endemic setting, respectively (Fig 1). This
is mainly the result of the combination of a relative long incubation period of leprosy and
detection delay. Areas that reach very low levels of NCDR require continuous monitoring for
many more years to prevent maintenance or even re-emergence of M. leprae.
In this study we did not consider the impact of a test for asymptomatic infection for future
NCDR, because such a test is only relevant if we assume that all infected individuals are infectious
(i.e. can infect other people). In our model, we assumed that only infected individuals who prog-
ress to MB leprosy are infectious, implying those who progress to PB leprosy and those who do
not develop leprosy do not contribute to the transmission. This assumption was made because it
is still poorly understood whether and to which extent asymptomatic infected are infectious.
This study used previously published quantifications of the model based on the population
and leprosy epidemiology in Nilphamari and Rangpur districts in Bangladesh. The advantage
of using this quantification is that it was based on the COLEP study, which includes a large
amount of very detailed information on this population, including data on the prevalence of
cases among contacts of different household sizes and the prevalence of cases among different
types of relatives [4]. The downside is that quantifications are based on 2003 data, which does
not truly reflect current leprosy epidemiology. However, for the purpose of assessing potential
impact of a diagnostic test this is less of an issue.
The primary concern of this study is about the extent to which our results are generalizable
to other regions or countries with leprosy in the world. The leprosy control program in the
Nilphamari and Rangpur districts of Bangladesh is more extensive than usual. The relative
short detection delay of two years and active household contact tracing with a coverage of 90%
is not common in leprosy control programs in other regions or countries. For that reason, we
conducted a sensitivity analysis in which we increased the passive case detection delay to six
years. Results show that fewer leprosy cases were prevented (S1 Table). The qualitative findings
of our main results (the importance of sensitivity and the impact and efficiency of household
contact tracing versus population survey) did not differ when implemented in a setting with a
less well-organized control program.
Another concern with respect to generalizability is the distribution of the MB/PB leprosy.
In Bangladesh the MB/PB ratio is approximately 20/80. Since we assumed in our model that
only MB cases are infectious, the impact of a diagnostic test might differ in areas with strik-
ingly different MB/PB ratios, such as in Brazil (65/35) or Indonesia (80/20) [5]. In a sensitivity
analysis, we showed that in a setting with a MB/PB ratio of 65/35, the benefit of a diagnostic
test is larger compared to our main results (S1 Table). This is because of the earlier detection
of relative more MB cases.
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Finally, this study did not look into combining the use of a diagnostic test for subclinical
leprosy with additional novel strategies, such as a chemoprophylaxis, as this is beyond the
scope of this study. Earlier modeling studies have shown that providing contacts with a single-
dose of rifampicin (SDR) chemoprophylaxis can reduce the transmission of leprosy over time
[11, 24]. It can be expected that adding chemoprophylaxis to our testing strategies would fur-
ther reduce the transmission of leprosy, especially if the test sensitivity is not optimal. In that
case, the contacts that were false negative might benefit from SDR.
Conclusions
We showed that a diagnostic test for subclinical leprosy could substantially reduce transmis-
sion in a high, medium and low endemic population. The test sensitivity influences the impact
on transmission in a population survey, but even with levels as low as 50% a substantial reduc-
tion could be achieved. To effectively reduce the NCDR in the short run, a population survey
is preferred over household contact tracing. However, this is only favorable in high endemic
settings, as in medium and low endemic settings testing in a population survey requires many
more people to be tested and treated to prevent one new leprosy case.
Supporting information
S1 Fig. Relative reduction of the new case detection rate (NCDR) of various testing strate-
gies compared to a strategy without testing (i.e. current control). Results present the relative
impact of testing in household contacts without follow-up, with a 3-year follow-up, and in a
population survey with a coverage of 50% and 100% under various assumptions of test sensi-
tivity in a high, medium and low endemic setting. High endemic is defined as 25 per 100,000
population, medium as 5 per 100,000, and low as 1 per 100,000. The relative impact on the
NCDR is calculated by dividing the NCDR of a testing strategy by the NCDR of the no testing
strategy.
(TIF)
S1 Table. Sensitivity analysis: A comparison of the benefit and cost of testing strategies in
three leprosy control settings. Results present the number of prevented new leprosy cases,
number needed to test and treat in three endemicity settings with a population of 1 million
after 10 years using a test with 70% sensitivity. We compared the leprosy control setting of our
main analysis to an area with a less-well organized leprosy control program in place (passive
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